window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 28, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

gastro-oesophageal junction cancer

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    AstraZeneca’s Imfinzi recommended by NICE for resectable gastric and gastro-oesophageal junction cancer

    AstraZeneca’s Imfinzi (durvalumab) has been recommended by NICE for use [...]

    May 14, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Pioneer launches regional accelerator programmes for life science and tech start-ups
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Manufacturing & Supply Chain, Medical devices, Research & Development
  • Fetal medicine pioneer recognised for expanding access to ultrasound education
    Categories: Clinical & Regulatory, Medical devices, Opinion & Events, Research & Development
  • Opella invests $70m in Mexico to expand Enterogermina production
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top